RxSight(RXST)

View 24 open jobs Website LinkedIn Careers Page

Focus: RxSight is a public ophthalmology company headquartered in Aliso Viejo, CA, specializing in adjustable intraocular lenses (Light Adjustable Lens technology) for cataract and aphakia correction. The company is transitioning from development to commercial-stage with revenue of $89M in FY 2025.

Ophthalmology

Profile data last refreshed 11h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

24-2 this month

Stable — net -2 jobs in 30d

19 added, 21 removed. Backfill posture.

Should You Work at RxSight?

AI assessment

Strong fit for commercial, regulatory, or clinical professionals betting on a single-asset company with clear market adoption but significant profitability and cash-position risk; higher risk for R&D-focused candidates.

Why Work Here

Publicly traded company with commercial momentum: revenue nearly doubled YoY from $49M (FY 2024) to $89M (FY 2025), signaling market traction for a novel technology.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$89M

Pipeline & Clinical Trials

Light Adjustable lens

Aphakia Cataract

N/A

Clinical Trials (1)

NCT07347379Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

N/A

Help build intelligence for RxSight

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

16 of 22 open roles are in Commercial, reflecting aggressive go-to-market execution in a high-margin ophthalmology niche with limited direct competition.

Recent leadership appointments (new CEO and CMO in July 2026) suggest strategic repositioning and potential for career acceleration in a smaller, agile organization.

Watch Out For

Significant cash burn: company posted $48.6M net loss on $89M revenue in FY 2025 with only $17M cash on hand, creating runway pressure and potential restructuring risk within 12–18 months.
Ultra-narrow pipeline: 9 total programs all centered on one modality (Light Adjustable Lens) and one indication (aphakia/cataract), with no Phase 1–3 trials listed—no diversification or late-stage catalysts.

Generated by Claude from RxSight's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

RxSight RxLAL

Cataract

N/A

Clinical Trials (1)

NCT03771352Clinical Study to Evaluate the RxSight Light Adjustable Lens With the Light Delivery Device in Subjects With Preoperative Corneal Astigmatism

N/A

Light Adjustable lens

Aphakia

N/A

Clinical Trials (1)

NCT03729024Exploratory Study to Evaluate Uncorrected Distance Vision and Quality of Vision After Light Treatments of an Implanted RxSight Light Adjustable Lens (RXLAL) With The Light Delivery Device (LDD) in Subjects With Preoperative Corneal Astigmatism

N/A

Light Adjustable lens

Aphakia

N/A

Clinical Trials (1)

NCT05202808RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study

N/A

Light Adjustable lens

Aphakia

N/A

Clinical Trials (1)

NCT04177771A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of Focus

N/A

Light Adjustable lens

Aphakia

N/A

Clinical Trials (1)

NCT03895034Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes

N/A

Light Adjustable lens

Aphakia

N/A

Clinical Trials (1)

NCT03660865Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive Surgery

N/A

Light Delivery Device

Aphakia

N/A

Clinical Trials (1)

NCT04005586A Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)

N/A

Light Adjustable lens

Aphakia

N/A

Clinical Trials (1)

NCT04529616Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual Outcomes

N/A

Interview Prep Quick Facts

Portfolio: 9 clinical trials

Top TAs: Ophthalmology

Publications: 2 in PubMed

SEC Filings: 2 available

Open Roles: 24 active jobs

Therapeutic Area Focus

Ophthalmology

9 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$89M82%

R&D Spend

$29M(33%)12%

Net Income

-$49M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

Reply: Light adjustable lens results of spherical equivalent and astigmatism correction from the United States Food and Drug Administration post approval study.

Journal of cataract and refractive surgery

2026

PMID:42615621

Light-adjustable lens results of spherical equivalent and astigmatism correction from the U.S. Food and Drug Administration postapproval study.

Journal of cataract and refractive surgery

2026

PMID:41664266

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

RxSight(RXST)

Should You Work at RxSight?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · RxSight(10)

Open Jobs (24)

Senior Scientist, Analytical Chemistry

Assistant Scientist

Customer Onboarding Specialist I

Clinical Specialist

Clinical Specialist

Account Manager (Northeast)

Account Manager (Northeast)

Senior Machinist

Account Manager (Southeast)

Sales Analyst

Account Manager (South Central)

Account Manager (South Central)

Account Manager (Southeast)

Account Manager (Southeast)

Account Manager (North Central)

Account Manager (North Central)

R&D Cleanroom Technician II

Senior Quality Engineer I

Account Manager (North Central)

Account Manager (Mountain West)

Account Manager (Southeast)

Account Manager (Southeast)

Account Manager (North Central)

General Consideration

Financials (FY2025)

Hiring Trend

Research Publications(2)